Lonza and Genetix Biotherapeutics renewed and expanded their commercial manufacturing agreement to support growing demand for ZYNTEGLO, the FDA‑approved gene therapy for transfusion‑dependent beta‑thalassemia. The extension secures continued production at Lonza’s Houston cell and gene therapy site and includes provisions to scale capacity for future Genetix programs. Both companies framed the move as strengthening commercial supply reliability for a curative therapy and illustrating CDMO‑developer partnerships as central to scaling advanced‑therapy manufacturing.